We are live on ! Find out more
AQST icon

Aquestive Therapeutics
AQST

46 hedge funds and large institutions have $18.7M invested in Aquestive Therapeutics in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

73% more capital invested

Capital invested by funds: $10.8M → $18.7M (+$7.87M)

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

2% more funds holding

Funds holding: 45 → 46 (+1)

4.07% less ownership

Funds ownership: 33.87% → 29.79% (-4.1%)

21% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 14

Holders
46
Holders Change
+1
Holders Change %
+2.22%
% of All Funds
0.79%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
7
Increased
11
Reduced
14
Closed
6
Calls
$28K
Puts
–
Net Calls
+$28K
Net Calls Change
+$4K

Top Buyers

Rank Fund Capital Flow
1
SSA
Schonfeld Strategic Advisors
New York
+$368K
2
VAFP
Vahanian & Associates Financial Planning
New York
+$157K
3
HighTower Advisors
HighTower Advisors
Illinois
+$147K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$137K
5
Man Group
Man Group
United Kingdom
+$102K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$715K
2
Renaissance Technologies
Renaissance Technologies
New York
-$368K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$114K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$106K
5
CAC
Cowen and Company
New York
-$80K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$25K -$1.05K -928 -4%
Mackenzie Financial
27
Mackenzie Financial
Ontario, Canada
$24K -$46.8K -41,381 -67%
Royal Bank of Canada
28
Royal Bank of Canada
Ontario, Canada
$23K +$22.7K +20,087 New
Citadel Advisors
29
Citadel Advisors
Florida
$21K -$61K -53,932 -75%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$17K – – –
GCP
31
GSA Capital Partners
United Kingdom
$16K +$15.5K +13,704 New
DBRC
32
D.B. Root & Company
Pennsylvania
$14K – – –
RPCA
33
Running Point Capital Advisors
California
$12K – – –
BCM
34
Bayesian Capital Management
New York
$12K +$11.6K +10,235 New
UBS Group
35
UBS Group
Switzerland
$11K +$9.78K +8,653 +2,085%
QT
36
Quantbot Technologies
New York
$4K – – –
Rockefeller Capital Management
37
Rockefeller Capital Management
New York
$3K – – –
JP Morgan Chase
38
JP Morgan Chase
New York
$3K +$809 +716 +41%
Osaic Holdings
39
Osaic Holdings
Arizona
$2K – – –
First Manhattan
40
First Manhattan
New York
$1K -$1.13K -1,000 -50%
TWA
41
TCI Wealth Advisors
Arizona
$1K +$226 +200 +67%
CUAMC
42
China Universal Asset Management Company
China
$1K +$564 +499 New
Bank of Montreal
43
Bank of Montreal
Ontario, Canada
$21 +$600 +531 +3%
D.E. Shaw & Co
44
D.E. Shaw & Co
New York
– -$106K -164,607 Closed
CAC
45
Cowen and Company
New York
– -$80K -124,590 Closed
VF
46
Virtu Financial
New York
– -$68K -106,408 Closed
EGM
47
Engineers Gate Manager
New York
– -$12K -18,261 Closed
Simplex Trading
48
Simplex Trading
Illinois
– -$16.4K -14,531 Closed
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
– -$727 -1,136 Closed
Citigroup
50
Citigroup
New York
– -$205 -181 -31%
1
2
3

AQST Hedge Fund Activity: Q3 2022 in Review

46 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q3 2022, worth a combined $18.7M — up 73% from $10.8M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new AQST positions and 6 closed out — a net gain of 1 holder — while 11 added to existing stakes and 14 trimmed.

The largest buyer was Schonfeld Strategic Advisors, adding an estimated $368K. The largest seller was Millennium Management, cutting an estimated $715K.

  • 46 institutional investors held Aquestive Therapeutics (AQST) as of Q3 2022, up from 45 in Q2 2022.
  • Funds reported $18.7M of Aquestive Therapeutics stock for Q3 2022, up 73% quarter-over-quarter.
  • 7 funds opened new Aquestive Therapeutics positions in Q3 2022 and 6 closed out, a net change of +1 holder.
  • The largest Aquestive Therapeutics buyer in Q3 2022 was Schonfeld Strategic Advisors, an estimated $368K added.
  • The largest Aquestive Therapeutics seller in Q3 2022 was Millennium Management, an estimated $715K sold.

Based on aggregated 13F filings for Q3 2022.